Methylphenidate in children with hyperactivity: review and cost–utility analysis

@article{Gilmore2001MethylphenidateIC,
  title={Methylphenidate in children with hyperactivity: review and cost–utility analysis},
  author={Anna B Gilmore and Ruairidh Milne},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2001},
  volume={10}
}
  • A. GilmoreR. Milne
  • Published 1 March 2001
  • Medicine, Psychology
  • Pharmacoepidemiology and Drug Safety
OBJECTIVE To evaluate the effectiveness and cost effectiveness of methylphenidate in the treatment of children with hyperkinetic disorder as defined using ICD-10 criteria. [] Key MethodDESIGN Comprehensive literature review and cost utility analysis comparing methylphenidate treatment with placebo. Costs and effects were estimated from a NHS perspective according to the methodology developed by the previous South and West Development and Evaluation Committee.

Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

The purpose of Drug Effectiveness Review Project reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. Reports are not usage

Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Update 4 Report

The purpose of Drug Effectiveness Review Project reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. Reports are not usage

Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil

MP-IR treatment of children and adolescents from Brazil is cost-effective for ADHD patients from the Brazilian public health system perspective, and both patients and the healthcare system might benefit from such a strategy.

Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD

  • S. NarayanJ. Hay
  • Psychology, Medicine
    Expert review of pharmacoeconomics & outcomes research
  • 2004
The cost effectiveness in choosing methylphenidate or amphetamine/ dextroamphetamine mixed salts (Adderall) as a first-line agent in the treatment of attention deficit hyperactivity disorder is evaluated.

Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

There is no comparative effectiveness or cost-effectiveness study comparing the two drugs, Guanfacine extendedrelease and atomoxetine, which are the only non-stimulants approved by the US Food and Drug Administration for once-daily use in the treatment of children and adolescents with ADHD.

Drug Class Review on Pharmacologic Treatments for ADHD

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage

Drug Class Review on Pharmacologic Treatments for ADHD: Final Report

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage

Cost-Effectiveness of Interventions for Children and Adolescents with Psychiatric Disorders

An overview of the cost-effectiveness of interventions for the major burdensome mental health disorders occurring during childhood and adolescence: autism spectrum disorders, attention-deficit/hyperactivity disorder, and conduct disorders is provided.

The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial

This is the first randomised controlled trial showing the short-term benefit of MPD on simplified Conners scores in NF1 children, and the main outcome was an improvement in scores on the simplified Conner’s Parent Rating Scale.
...

References

SHOWING 1-10 OF 38 REFERENCES

Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour

The results support the validity of a construct of hyperactivity in describing childhood psychopathology, but emphasize the need for a refinement of diagnostic criteria.

Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.

Stimulant medication within this therapeutic range, therefore, results in few, generally mild side effects, and Surprisingly, a high frequency of these behavior side effects were reported during the placebo condition.

Methylphenidate and growth in hyperactive children. A controlled withdrawal study.

The results document a linkage between exposure to methylphenidate and reduction in growth velocity, however, they do not address whether the medication has long-term effects on height.

Vicissitudes of follow-up studies: differential effects of parent training and stimulant medication with hyperactives.

A two-year outcome study of 73 hyperactive children supports both previous short-term studies which suggested that stimulant medication is superior to parent training and long-term studies which

One-year follow-up of hyperactive boys treated with imipramine or methylphenidate.

There was a higher rate of discontinuance of imipramine than of methylphenidate in this sample of hyperactive boys, and both medications decreased the boys' rate of weight gain but had no significant effect on growth in height.

NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale.

OBJECTIVE The National Institute of Mental Health's recently initiated 5-year, multisite, multimodal treatment study of children with attention-deficit hyperactivity disorder (MTA) is the first major

Assessment of Stimulant Response in ADHD Children Using a Refined Multimethod Clinical Protocol

The data indicate a statistically significant medication response on most measures, as well as a significant difference between the low and moderate doses on some measures.

Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children.

Analysis of the clinical significance of effects indicated that large proportions of treated children exhibited significantly improved or normalized classroom functioning; however, a large subset of them failed to show improved academic functioning.

Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height.

The findings indicated that methylphenidate therapy does not compromise final height, even when it has an adverse impact on children's growth rate during the active treatment phase, and a compensatory growth rate appears to occur following discontinuation of stimulant therapy.

Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Although some children are being diagnosed as having ADHD with insufficient evaluation and in some cases stimulant medication is prescribed when treatment alternatives exist, there is little evidence of widespread overdiagnosis or misdiagnosis of ADHD or ofidespread overprescription of methylphenidate by physicians.